Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | NLRP3 | Q96P20 | 11/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18530334 | 0.89 | KMT2A (0.58) | ALDH1A1CYP1A2MEN1KMT2ANLRP3 | |
| SCHEMBL10580750 | 0.89 | ALDH1A1 (0.68) | ALDH1A1CYP1A2MEN1KMT2ANLRP3 | |
| SCHEMBL31570060 | 0.89 | ALDH1A1 (0.68) | ALDH1A1CYP1A2MEN1KMT2ANLRP3 | |
| SCHEMBL9799670 | 0.88 | ALDH1A1 (0.61) | ALDH1A1CYP1A2MEN1KMT2ANLRP3 | |
| SCHEMBL11403762 | 0.86 | NLRP3 (0.62) | ALDH1A1CYP1A2MEN1KMT2ANLRP3 | |
| SCHEMBL4602459 | 0.86 | NLRP3 (0.62) | ALDH1A1CYP1A2MEN1KMT2ANLRP3 | |
| SCHEMBL127182 | 0.86 | CA1 (0.61) | ALDH1A1CYP1A2MEN1KMT2ANLRP3 | |
| SCHEMBL6360996 | 0.86 | RAB9A (0.69) | ALDH1A1CYP1A2MEN1KMT2ANLRP3 | |
| SCHEMBL441932 | 0.86 | HDAC4 (0.67) | ALDH1A1CYP1A2MEN1KMT2ANLRP3 | |
| SCHEMBL14202768 | 0.86 | ALDH1A1 (0.59) | ALDH1A1CYP1A2MEN1KMT2ANLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043076-A1 | Substituted 2-arylmethylene-n-aryl-n'aryl-malonamides and analogs as activators of caspases and inducers of apoptosis | CYTOVIA, INC. | 2007-02-22 | — | — | US | disclosed |
| WO-2005037196-A2 | SUBSTITUTED 2-ARYLMETHYLENE-N-ARYL-N'-ARYL-MALONAMIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | CYTOVIA, INC. (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043076-A1 | Substituted 2-arylmethylene-n-aryl-n'aryl-malonamides and analogs as activators of caspases and inducers of apoptosis | CASP14, CASP2, CASP3 | ALDH1A1 952/4885CYP1A2 475/4885MEN1 2893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.